<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286102</url>
  </required_header>
  <id_info>
    <org_study_id>11005</org_study_id>
    <nct_id>NCT02286102</nct_id>
  </id_info>
  <brief_title>A Prospective Randomized Study on the Clinical Benefits of OrthoPAT Drains</brief_title>
  <official_title>A Prospective Randomized Study on the Clinical Benefits of OrthoPAT Drains for Adults Undergoing Multilevel Spine Surgery for Deformity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The examination of the ability of the OrthoPATÂ® blood collection device to decrease the
      transfusion rate and volume of adults undergoing posterior spine surgery for deformity
      correction of 6 levels or more.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the use of postoperative drains with blood
      salvage capabilities to determine if they decrease both the volume and rate of allogenic
      blood transfusion in adult patients undergoing multilevel spine surgery for deformity. In
      addition, the ability of these drains to decrease the complications that are associated with
      allogenic blood exposure (postoperative infection, volume overload and transfusion reactions)
      will also be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">October 17, 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of Allogenic Blood Transfused Postoperatively</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>The total volume of allogenic blood transfused postoperatively will be measured during the first 48 hours postoperatively while the drains are in place.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Levels, Post-Op Day 3</measure>
    <time_frame>3 days postop</time_frame>
    <description>Hemoglobin levels will be measured post-operatively day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Levels, Post-Op Day 2</measure>
    <time_frame>2 days postop</time_frame>
    <description>Hemoglobin levels will be measured post-operatively day 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Spine Deformity</condition>
  <arm_group>
    <arm_group_label>OrthoPAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Constavac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OrthoPAT</intervention_name>
    <description>OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
    <arm_group_label>OrthoPAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Constavac</intervention_name>
    <description>Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
    <arm_group_label>Constavac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patient is at least 18 years of age The patient is to undergo posterior spine surgery
        in the thoracic or lumbar region for deformity correction of greater than 6 levels The
        patient has signed a patient Informed Consent

        Exclusion Criteria:

        The patient is less than 18 years of age The patient has a hematologic disorder of any
        etiology The patient has received active anticoagulant therapy, including aspirin, Plavix,
        Heparin, Lovenox or Coumadin within one week of admission The patient has a known active
        infection or malignancy. The patient has a terminal illness with a life expectancy of less
        than one year.

        The patient requires immuno-suppressive therapy. The patient is undergoing a combined
        anterior/posterior fusion. The patient has a history of drug or alcohol abuse that may
        interfere with his/her ability to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oheneba Boachie-Adjei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>June 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 25, 2017</results_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Constavac</title>
          <description>Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
Constavac: Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
        </group>
        <group group_id="P2">
          <title>OrthoPAT</title>
          <description>Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
OrthoPAT: OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Constavac</title>
          <description>Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
Constavac: Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
        </group>
        <group group_id="B2">
          <title>OrthoPAT</title>
          <description>Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
OrthoPAT: OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Volume of Allogenic Blood Transfused Postoperatively</title>
        <description>The total volume of allogenic blood transfused postoperatively will be measured during the first 48 hours postoperatively while the drains are in place.</description>
        <time_frame>48 hours postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Constavac</title>
            <description>Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
Constavac: Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
          </group>
          <group group_id="O2">
            <title>OrthoPAT</title>
            <description>Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
OrthoPAT: OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Allogenic Blood Transfused Postoperatively</title>
          <description>The total volume of allogenic blood transfused postoperatively will be measured during the first 48 hours postoperatively while the drains are in place.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458.33" spread="4.28"/>
                    <measurement group_id="O2" value="382.35" spread="62.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Levels, Post-Op Day 3</title>
        <description>Hemoglobin levels will be measured post-operatively day 3</description>
        <time_frame>3 days postop</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Constavac</title>
            <description>Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
Constavac: Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
          </group>
          <group group_id="O2">
            <title>OrthoPAT</title>
            <description>Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
OrthoPAT: OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Levels, Post-Op Day 3</title>
          <description>Hemoglobin levels will be measured post-operatively day 3</description>
          <units>g/Dl (grams/deciliter)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.07" spread=".79"/>
                    <measurement group_id="O2" value="9.9" spread=".99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Levels, Post-Op Day 2</title>
        <description>Hemoglobin levels will be measured post-operatively day 2</description>
        <time_frame>2 days postop</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Constavac</title>
            <description>Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
Constavac: Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
          </group>
          <group group_id="O2">
            <title>OrthoPAT</title>
            <description>Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
OrthoPAT: OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Levels, Post-Op Day 2</title>
          <description>Hemoglobin levels will be measured post-operatively day 2</description>
          <units>g/Dl (grams/deciliter)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.33" spread=".88"/>
                    <measurement group_id="O2" value="10.19" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of surgery to post-op day 3.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OrthoPAT</title>
          <description>Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
OrthoPAT: OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
        </group>
        <group group_id="E2">
          <title>Constavac</title>
          <description>Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
Constavac: Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Oheneba Boachie-Adjei, MD</name_or_title>
      <organization>Hospital for Special Surgery</organization>
      <phone>212 606-1723</phone>
      <email>rosst@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

